Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Trends
Gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections). Gene therapy involves “vectors” which can be either viral or non-viral vectors. The choice of a particular AAV to use as a gene transfer vector is heavily reliant on several critically important criteria: (1) which cell/tissue types are being targeted; (2) the safety profile associated with the delivered gene; (3) the choice of systemic versus local delivery; and (4) the use of tissue-specific or constitutively active promoters.
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market key facts
In the year 2017, the total prevalent cases of selected indications for AAV Gene Therapies were 2,718,559 in the 7MM.
The total prevalent cases of Hemophilia A and Hemophilia B were reported to be 42,458 and 10,615, respectively, in the year 2017 in the 7MM.
The total number of treated cases of Pompe disease was 11,928 in 2017, and 111,768 cases comprised of Retinitis Pigmentosa in the same year.
DelveInsight's "Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market, historical and forecasted epidemiology, the pipeline insight as well as the Adeno-Associated Virus (AAV) Vectors in Gene Therapy market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Trends
The Adeno-Associated Virus (AAV) Vectors in Gene Therapy market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Adeno-Associated Virus (AAV) Vectors in Gene Therapy market trends by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Adeno-Associated Virus (AAV) Vectors in Gene Therapy market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology Forecast
The Adeno-Associated Virus (AAV) Vectors in Gene Therapy epidemiology section covers insights about historical and current Adeno-Associated Virus (AAV) Vectors in Gene Therapy patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognise the causes of current and forecasted Adeno-Associated Virus (AAV) Vectors in Gene Therapy Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Analysis
The Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline and Drugs Uptake section focus on the rate of uptake of the potential drugs recently launched in the Adeno-Associated Virus (AAV) Vectors in the Gene Therapy market or expected to get launched in the market during the study period. The analysis covers the Adeno-Associated Virus (AAV) Vectors in Gene Therapy market uptake by drugs, patient uptake by therapies, and drug
For more details, visit:
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market Trends